Selexis CHO Cells in Suspension-1

Latest News

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

OCTOBER 31, 2022
2 min read

KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer

KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as...

Read More
3 min read

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma...

Read More
JULY 6, 2022
3 min read

KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland

The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the...

Read More